Cargando…
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury
Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 match...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552425/ https://www.ncbi.nlm.nih.gov/pubmed/34709533 http://dx.doi.org/10.1007/s11239-021-02597-y |
_version_ | 1784591372497453056 |
---|---|
author | Lippi, Giuseppe Szergyuk, Ivan de Oliveira, Maria Helena Santos Benoit, Stefanie W. Benoit, Justin L. Favaloro, Emmanuel J. Henry, Brandon Michael |
author_facet | Lippi, Giuseppe Szergyuk, Ivan de Oliveira, Maria Helena Santos Benoit, Stefanie W. Benoit, Justin L. Favaloro, Emmanuel J. Henry, Brandon Michael |
author_sort | Lippi, Giuseppe |
collection | PubMed |
description | Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = − 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-021-02597-y. |
format | Online Article Text |
id | pubmed-8552425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-85524252021-10-28 The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury Lippi, Giuseppe Szergyuk, Ivan de Oliveira, Maria Helena Santos Benoit, Stefanie W. Benoit, Justin L. Favaloro, Emmanuel J. Henry, Brandon Michael J Thromb Thrombolysis Article Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = − 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-021-02597-y. Springer US 2021-10-28 2022 /pmc/articles/PMC8552425/ /pubmed/34709533 http://dx.doi.org/10.1007/s11239-021-02597-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Lippi, Giuseppe Szergyuk, Ivan de Oliveira, Maria Helena Santos Benoit, Stefanie W. Benoit, Justin L. Favaloro, Emmanuel J. Henry, Brandon Michael The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title | The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title_full | The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title_fullStr | The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title_full_unstemmed | The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title_short | The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
title_sort | role of lipoprotein(a) in coronavirus disease 2019 (covid-19) with relation to development of severe acute kidney injury |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552425/ https://www.ncbi.nlm.nih.gov/pubmed/34709533 http://dx.doi.org/10.1007/s11239-021-02597-y |
work_keys_str_mv | AT lippigiuseppe theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT szergyukivan theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT deoliveiramariahelenasantos theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT benoitstefaniew theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT benoitjustinl theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT favaloroemmanuelj theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT henrybrandonmichael theroleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT lippigiuseppe roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT szergyukivan roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT deoliveiramariahelenasantos roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT benoitstefaniew roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT benoitjustinl roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT favaloroemmanuelj roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury AT henrybrandonmichael roleoflipoproteinaincoronavirusdisease2019covid19withrelationtodevelopmentofsevereacutekidneyinjury |